ChinaBio Partnering Forum 2014 opened on May 7 in Suzhou Industrial Park. Jointly organized by ChinaBio and EBD Group in association with BioBay, the two-day event focused on the frontier trend of global cooperation in life science. Over eight hundred representatives from the world's leading biotech and pharmaceutical companies discussed financing, cross-border cooperation, and intellectual property right protection. The 2010 and 2012 sessions of the country's biggest life science cooperation forum were also held in SIP.

Bayer, AstraZeneca, Abbott Laboratories, Johnson & Johnson Medical, MSD, Sanofi, and Lundbeck were looking for Chinese partners. Law firms, venture capital organizations, and industrial associations were looking for opportunities to play a part in and benefit from the rising life science sector. The forum created an international cooperation platform connecting all players. Among 800 participants, nearly a fourth came from foreign countries.

The keynote speakers talked about Chinese and global trends of biomedicine, reviewed the successes of Chinese company from different perspectives of cooperation, innovation, and investment. The one-on-one meetings helped small R&D enterprises reach out to domestic and foreign resources. The roadshow had been proven effective in demonstrating the latest technologies and products, publicizing cooperation intents, and finding partners.

BioBay gathered 370 hi-tech life science R&D companies and created several industrial clusters in drug development, medical device, biotechnology, and nanotech. It is also the workplace for nearly 8,000 professionals. "The industrial chain in modern time is actually an interactive ecosystem," said CEO Liu Yuwen of BioBay. "So we're thinking about how to create an industrial ecosystem based on diverse and professional services so as to reinforce regional and even international connection." As a result, BioBay has focused its services on business development and industry promotion.

In fact, a group of local companies have benefited from upstream and downstream cooperation. Alphamab is one of them. The company has applied for clinical approval for a macromolecules generic drug and is to get official certificate on a type 1.1 new drug. It signed 15 technology transfer contracts with Chia-Tai Tianqing Pharmacy, Qilu Pharmaceutical, Shanghai CP Guojian Pharmaceutical, Livzon Pharmaceutical, Ningbo Renjian Pharmaceutical, and Innovent Biologics based at BioBay. The total value of these contracts amounts to over 200 million yuan. The fruitful interactions among market leaders multiply the value of individual companies and finally result in win-win cooperation.